Подписаться
Violeta Serra, PhD
Violeta Serra, PhD
Principal Investigator
Подтвержден адрес электронной почты в домене vhio.net - Главная страница
Название
Процитировано
Процитировано
Год
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
S Chandarlapaty, A Sawai, M Scaltriti, V Rodrik-Outmezguine, ...
Cancer cell 19 (1), 58-71, 2011
10532011
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
V Serra, B Markman, M Scaltriti, PJA Eichhorn, V Valero, M Guzman, ...
Cancer research 68 (19), 8022-8030, 2008
9192008
Development of PI3K inhibitors: lessons learned from early clinical trials
J Rodon, R Dienstmann, V Serra, J Tabernero
Nature reviews Clinical oncology 10 (3), 143-153, 2013
8532013
Interrogating open issues in cancer precision medicine with patient-derived xenografts
AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ...
Nature Reviews Cancer 17 (4), 254-268, 2017
6422017
Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor–positive breast cancer
MT Herrera-Abreu, M Palafox, U Asghar, MA Rivas, RJ Cutts, ...
Cancer research 76 (8), 2301-2313, 2016
6322016
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ...
Oncogene 30 (22), 2547-2557, 2011
5952011
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition
YH Ibrahim, C García-García, V Serra, L He, K Torres-Lockhart, A Prat, ...
Cancer discovery 2 (11), 1036-1047, 2012
5902012
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
PJA Eichhorn, M Gili, M Scaltriti, V Serra, M Guzman, W Nijkamp, ...
Cancer research 68 (22), 9221-9230, 2008
5852008
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors
R Dienstmann, J Rodon, V Serra, J Tabernero
Molecular cancer therapeutics 13 (5), 1021-1031, 2014
5172014
A decade of clinical development of PARP inhibitors in perspective
J Mateo, CJ Lord, V Serra, A Tutt, J Balmaña, M Castroviejo-Bermejo, ...
Annals of Oncology 30 (9), 1437-1447, 2019
5162019
A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds
A Bruna, OM Rueda, W Greenwood, AS Batra, M Callari, RN Batra, ...
Cell 167 (1), 260-274. e22, 2016
4382016
Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor?
T Von Zglinicki, V Serra, M Lorenz, G Saretzki, R Lenzen-Groβimlighaus, ...
Laboratory investigation 80 (11), 1739-1747, 2000
3762000
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
M Scaltriti, PJ Eichhorn, J Cortés, L Prudkin, C Aura, J Jiménez, ...
Proceedings of the National Academy of Sciences 108 (9), 3761-3766, 2011
3692011
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
H Dev, TWW Chiang, C Lescale, I de Krijger, AG Martin, D Pilger, ...
Nature cell biology 20 (8), 954-965, 2018
3472018
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ...
Science translational medicine 7 (283), 283ra51-283ra51, 2015
3392015
Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening
V Serra, T Von Zglinicki, M Lorenz, G Saretzki
Journal of Biological Chemistry 278 (9), 6824-6830, 2003
3342003
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, ...
Annals of Oncology 29 (5), 1203-1210, 2018
3312018
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer
M Elkabets, S Vora, D Juric, N Morse, M Mino-Kenudson, T Muranen, ...
Science translational medicine 5 (196), 196ra99-196ra99, 2013
3102013
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
RE Miller, A Leary, CL Scott, V Serra, CJ Lord, D Bowtell, DK Chang, ...
Annals of Oncology 31 (12), 1606-1622, 2020
2812020
CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer
SF Johnson, C Cruz, AK Greifenberg, S Dust, DG Stover, D Chi, ...
Cell reports 17 (9), 2367-2381, 2016
2592016
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20